phosphorodiamid
morpholino
oligom
pmo
short
singlestrand
dna
analog
built
upon
backbon
morpholin
ring
connect
phosphorodiamid
linkag
uncharg
nucleic
acid
analog
pmo
bind
complementari
sequenc
target
mrna
watsoncrick
base
pair
block
protein
translat
steric
blockad
pmo
interfer
viral
protein
translat
oper
independ
rnase
h
meanwhil
pmo
resist
varieti
enzym
present
biolog
fluid
characterist
make
highli
suitabl
vivo
applic
notabl
pmobas
therapi
duchenn
muscular
dystrophi
dmd
approv
unit
state
food
drug
administr
hallmark
pmobas
antisens
therapi
review
develop
histori
pmo
deliveri
method
improv
cellular
uptak
neutral
charg
pmo
molecul
past
studi
pmo
antagon
rna
dna
virus
pmo
target
select
remain
question
pmo
antivir
strategi
discuss
detail
new
insight
provid
frontier
microbiolog
wwwfrontiersinorg
april
volum
articl
frontier
microbiolog
wwwfrontiersinorg
disclaim
mention
trade
name
commerci
product
articl
sole
purpos
provid
specif
inform
impli
recommend
endors
research
realiz
decad
ago
antisens
nucleic
acid
could
use
treat
diseas
sinc
antisens
therapi
use
varieti
nucleic
acid
nucleic
acid
analog
evalu
use
therapeut
compound
numer
applic
among
candid
treatment
morpholino
oligo
also
known
phosphorodiamid
morpholino
oligom
pmo
demonstr
promis
effect
development
biolog
research
involv
gene
knockdown
well
clinic
trial
focus
treatment
genet
disord
summerton
specif
pmo
short
singlestrand
dna
analog
contain
backbon
morpholin
ring
connect
phosphorodiamid
linkag
summerton
due
neutral
charg
properti
less
like
interact
protein
maintain
bind
nucleic
acid
moulton
jiang
specif
pmo
bind
complementari
sequenc
target
mrna
watsoncrick
base
pair
block
mrna
translat
sequencespecif
steric
blockad
process
distinct
rnase
hdepend
mechan
protein
translat
inhibit
induc
antisens
compound
phosphorothio
dna
summerton
importantli
pmo
resist
varieti
enzym
biolog
fluid
make
highli
suitabl
vivo
applic
hudziak
et
al
date
pmobas
therapi
duchenn
muscular
dystrophi
dmd
shown
great
success
bypass
effect
gene
mutat
underli
human
diseas
specif
pmobas
therapi
restor
product
function
dystrophin
alter
rna
splice
remov
mutat
dystrophin
exon
disrupt
downstream
fulllength
dystrophin
protein
translat
mutat
mrna
drug
approv
us
food
drug
administr
avail
market
trade
name
exondi
tm
eteplirsen
approv
exondi
tm
hallmark
pmobas
antisens
therapi
demonstr
potenti
safeti
effect
pmo
technolog
drive
futur
develop
therapi
treatment
diseas
asid
genet
disord
pmo
therapi
also
evalu
treatment
broad
categori
untreat
diseas
includ
viral
infect
antibioticresist
bacteri
infect
cancer
enterlein
et
al
warfield
et
al
cansizoglu
toprak
chen
et
al
review
pmo
background
well
research
focus
intracellular
deliveri
pmo
pmo
efficaci
dna
rna
virus
pmo
target
select
outlin
final
current
challeng
develop
success
pmo
antivir
strategi
discuss
detail
new
insight
provid
concept
antisens
oligonucleotid
potenti
therapeut
agent
first
demonstr
experiment
target
translat
initi
site
within
rou
sarcoma
viru
rna
mechan
initi
explain
particip
format
rnadna
duplex
viral
rna
steric
block
viral
gene
express
ultim
prevent
viral
replic
zamecnik
stephenson
subsequ
studi
reveal
also
particip
second
inhibitori
mechan
involv
rna
dna
duplex
recognit
cellular
enzym
rnase
h
result
rna
cleavag
abrog
viru
gene
express
well
tadokoro
kanaya
recent
rnase
hmediat
degrad
target
rna
shown
main
rnainterfer
mechan
respons
microrna
mirna
small
interfer
rna
sirna
dnadirect
rna
interfer
saurabh
et
al
due
effect
specif
technolog
subsequ
attract
attent
global
research
tool
therapeut
purpos
davi
et
al
millingtonward
et
al
wittrup
lieberman
first
antisens
test
clinic
trial
begin
design
target
treatment
acut
myelogen
leukemia
bayev
et
al
medic
mileston
applic
antisens
technolog
first
antisens
drug
fomivirsen
approv
fda
treatment
cytomegaloviru
retin
immunodefici
patient
marwick
wikipedia
sinc
numer
antisens
drug
test
clinic
trial
varieti
human
diseas
date
five
antisens
compound
receiv
market
author
fda
includ
eteplirsen
current
ongo
clinic
trial
antisens
compound
list
websit
clinicaltrialsgov
godfrey
et
al
howev
compar
tradit
drug
develop
industri
develop
therapeut
sirna
dnabas
analog
control
gene
express
less
success
exemplifi
remov
first
commerci
avail
antisens
drug
fomivirsen
market
key
featur
underli
effect
antisens
nucleas
resist
help
remain
intact
hour
extracellular
medium
within
cell
summerton
methylphosphonatelink
dna
analog
develop
late
constitut
major
advanc
emerg
antisens
field
result
product
first
antisens
drug
exhibit
accept
stabil
biolog
system
hudziak
et
al
howev
addit
stabil
specif
rnasehbas
antisens
therapi
import
concern
sinc
rnaseh
cleav
dnarna
duplex
short
pair
length
highli
activ
duplex
base
pair
length
monia
et
al
summerton
therefor
rnasehindepend
steric
blockag
antisens
may
safer
strategi
notabl
effect
target
region
steric
block
agent
inhibit
translat
gener
limit
utr
untransl
region
start
codon
region
mrna
achiev
good
specif
fewer
advers
offtarget
effect
furthermor
bind
rnase
hindepend
antisens
partial
match
rna
sequenc
unlik
biolog
consequ
lebleu
et
al
oligom
possess
morpholino
phosphorodiamid
backbon
also
call
pmo
figur
constitut
novel
type
analog
synthes
ribosid
ribos
ring
open
oxid
reclos
use
ammonia
form
substitut
morpholin
moieti
summerton
weller
next
phosphodiest
intersubunit
bond
replac
phosphorodiamid
linkag
summerton
weller
pmo
demonstr
excel
resist
nucleas
figur
comparison
chemic
structur
pmo
dna
illustr
phosphorodiamid
morpholino
oligom
pmo
contain
backbon
morpholin
ring
connect
phosphorodiamid
linkag
ribos
ring
open
oxid
reclos
use
ammonia
form
substitut
morpholin
moieti
phosphodiest
intersubunit
bond
replac
phosphorodiamid
linkag
proteas
esteras
varieti
enzym
present
biolog
fluid
hudziak
et
al
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
ms
analysi
demonstr
pmo
complet
resist
differ
hydrolas
serum
plasma
hudziak
et
al
bolster
pmo
suitabl
vivo
applic
hudziak
et
al
furthermor
uncharg
molecul
pmo
interact
strongli
protein
minim
hybridizationindepend
protein
interact
sinc
decreas
effect
like
due
charg
phosphorothio
backbon
moulton
jiang
hagedorn
et
al
pmo
bind
complementari
sequenc
target
mrna
watsoncrick
base
pair
block
translat
rnase
hindepend
steric
blockad
figur
lebleu
et
al
moreov
pmo
target
intronexon
junction
sequenc
capabl
modul
premrna
splice
well
figur
haven
hast
reason
antisens
pmo
revolutionari
tool
development
biolog
eisen
smith
microinject
pmo
egg
singl
paucicellular
zygot
pmo
apport
daughter
cell
cell
divis
ensur
deliveri
cell
subsequ
cell
prolifer
heasman
et
al
addit
use
studi
gene
function
embryon
develop
pmo
also
test
treatment
broad
rang
diseas
numer
clinic
trial
mainli
promot
avi
biopharma
inc
sarepta
biopharma
inc
howev
applic
unmodifi
pmo
greatli
limit
ineffici
vivo
deliveri
unless
rel
high
dose
administr
moulton
jiang
fact
anim
dmd
model
high
dose
unmodifi
pmo
inject
dystroph
muscl
need
induc
function
dystrophin
express
skelet
muscl
moulton
jiang
thu
two
form
pmo
distinct
chemic
modif
develop
facilit
intracellular
deliveri
pmo
includ
peptideconjug
pmo
ppmo
vivopmo
moreov
pmoplu
anoth
novel
form
posit
charg
pmo
morpholino
oligomerbas
backbon
recent
develop
latest
version
pmo
novel
pmo
form
discuss
detail
initi
techniqu
deliv
pmo
cultur
cell
base
mechan
deliveri
method
microinject
scrape
moulton
et
al
associ
limit
recent
addit
mechan
scrape
methodolog
electropor
use
endosom
escap
reagent
evalu
improv
deliveri
cytosol
nuclear
compart
tissu
cultur
partridg
et
al
moulton
jiang
current
intens
develop
wide
use
vivo
pmo
deliveri
strategi
base
use
argininerich
cell
penetr
peptid
cpp
lebleu
et
al
morco
et
al
cell
penetr
peptid
also
known
protein
transduct
domain
ptd
tatcpp
dietz
bahr
origin
identifi
discoveri
unexpect
properti
human
immunodefici
viru
hiv
transactiv
transcript
tat
protein
dietz
bahr
novel
activ
reveal
observ
tat
could
transactiv
ltr
promot
cross
cellular
nuclear
membran
dietz
bahr
subsequ
structur
analysi
pinpoint
short
peptid
locat
aa
tat
sequenc
grkkrrqrrrppq
respons
membranecross
activ
parent
tat
protein
vive
et
al
abe
et
al
novel
peptid
sequenc
later
name
cpp
evalu
abil
confer
membranecross
abil
protein
compound
includ
pmo
fluoresc
microscopi
flow
cytometri
analysi
cell
treat
fluoresceintag
pmo
cpp
conjug
remark
enhanc
cellular
uptak
pmo
compar
nonconjug
pmo
alonso
et
al
moreov
cation
peptid
conjug
pmo
shown
much
less
effect
pmo
conjug
tatcpp
tatcpp
significantli
enhanc
deliveri
pmo
nearli
cell
assay
moulton
et
al
furthermor
cppmediat
deliveri
much
simpler
procedur
conduct
mechan
deliveri
method
howev
tatcpp
mediat
pmo
deliveri
requir
high
pmo
concentr
achiev
therapeut
antisens
activ
cytotox
observ
meanwhil
tatcpp
pmo
conjug
studi
establish
conjug
associ
cell
membran
intern
conjug
local
vesicl
cytosol
nucleu
moulton
et
al
therefor
cpp
sequenc
optim
reduc
cytotox
increas
uptak
effici
enhanc
pmo
effect
concept
prompt
comparison
two
type
cpp
rxr
peptid
r
pen
peptid
lebleu
et
al
effici
cpp
studi
rahxr
r
ahx
repres
acid
spacer
lebleu
et
al
importantli
rahxr
rpmo
conjug
shown
effect
sever
murin
viral
infect
model
well
treatment
duchenn
muscular
dystrophi
unfortun
applic
effect
dose
approach
cytotox
level
obstacl
limit
use
clinic
set
abe
et
al
vivopmo
exploit
nonpeptidebas
transport
deliv
pmo
cultur
cell
tissu
morco
et
al
current
gene
tool
llc
philomath
unit
state
major
supplier
vivopmo
research
develop
applic
unlik
cppconjug
pmo
vivopmo
coval
link
molecular
scaffold
carri
dendrit
structur
assembl
around
triazin
core
hold
eight
guanidinium
head
group
optim
orient
cell
membran
penetr
morco
et
al
ferguson
et
al
vivopmo
effect
enter
vitro
cultur
cell
well
wide
varieti
mous
tissu
vivo
induc
correct
premrna
splice
error
detect
use
experiment
test
system
design
detect
event
cell
tissu
morco
et
al
compar
cpppmo
vivopmo
less
frequent
investig
inhibitori
effect
target
gene
howev
avail
data
suggest
least
knockdown
target
gene
achiev
use
vivopmo
advers
side
effect
vitro
vivo
guo
et
al
kang
et
al
nazmi
et
al
reissner
et
al
meanwhil
mous
model
studi
also
shown
intraven
iv
intraperiton
ip
administr
vivopmo
equal
efficaci
reissner
et
al
sartor
astonjon
furthermor
appear
vivopmo
less
cytotox
cpppmo
sinc
one
report
demonstr
cytotox
vivopmo
ferguson
et
al
appear
dendrim
vivopmo
capabl
induc
red
blood
cell
sediment
prompt
ferguson
et
al
recommend
oligonucleotid
analog
analyz
potenti
base
pair
hybrid
may
induc
dendrim
cluster
moreov
supplement
vivopmo
physiolog
salin
anticoagul
therapi
hold
promis
counteract
vivopmo
toxic
ferguson
et
al
compar
cppconjug
pmo
vivopmo
pmoplu
tm
newer
type
charg
pmo
contain
posit
charg
piperazin
group
within
molecular
backbon
pmoplu
recent
develop
form
pmo
studi
demonstr
type
pmo
well
toler
exhibit
improv
efficaci
numer
vivo
viral
infect
model
rel
pmo
therapi
swenson
et
al
warren
et
al
warren
et
al
warren
et
al
meng
et
al
howev
pmoplu
still
unavail
research
due
proprietari
statu
technolog
sole
own
avi
howev
report
avail
date
suggest
pmoplu
may
less
cytotox
cpppmo
phase
clinic
trial
evalu
pmoplu
compound
ebola
viru
healthi
male
femal
subject
year
age
six
doseexpans
cohort
subject
per
dosag
group
receiv
singl
iv
infus
activ
studi
drug
mgkg
pmoplu
result
demonstr
pmoplu
treatment
safe
well
toler
dose
studi
heald
et
al
safeti
superior
cpppmo
vivopmo
howev
systemat
investig
still
need
compar
vivopmo
pmoplu
regard
effici
stabil
cytotox
illustr
chemic
structur
cpppmo
vivopmo
pmoplu
tm
list
pmo
explor
antivir
compound
rna
virus
includ
ebola
viru
flaviviru
coronaviru
picornaviru
other
section
major
advanc
research
field
present
filovirus
includ
marburg
viru
ebola
viru
ebov
negativesens
singlestrand
rna
virus
highli
pathogen
caus
human
outbreak
viral
figur
chemic
structur
cpppmo
vivopmo
pmoplu
tm
pmo
conjug
cell
penetr
peptid
rahxr
r
ahx
repres
acid
spacer
vivopmo
coval
link
molecular
scaffold
carri
dendrit
structur
assembl
around
triazin
core
hold
eight
guanidinium
head
group
optim
orient
cell
membran
penetr
pmoplu
tm
charg
pmo
contain
posit
charg
piperazin
group
within
molecular
backbon
hemorrhag
fever
fatal
epidem
ebola
viru
diseas
caus
death
total
case
west
africa
fischer
et
al
current
commerci
vaccin
effect
therapeut
yet
avail
filoviru
infect
fischer
et
al
reynold
marzi
trad
et
al
antivir
drug
urgent
need
thu
peptideconjug
pmo
ppmo
nonconjug
pmo
test
ebola
viru
infect
cultur
cell
anim
model
earlier
studi
show
ppmo
target
translat
start
site
region
ebov
positivesens
rna
exhibit
sequencespecif
timeand
dosedepend
inhibit
ebov
replic
cultur
cell
enterlein
et
al
moreov
ppmo
provid
complet
protect
mice
administ
challeng
lethal
dose
ebov
interestingli
correspond
nonconjug
pmo
also
provid
protect
mice
administ
prophylact
well
meanwhil
anoth
report
year
demonstr
combin
ebovspecif
pmo
target
viral
mrna
rna
polymeras
l
protect
rodent
ebov
challeng
administ
exposur
studi
nonconjug
pmo
also
test
prophylact
proofofprincip
trial
rhesu
macaqu
wherebi
pmo
formul
protect
macaqu
lethal
ebov
infect
recent
pmoplu
also
shown
effect
ebola
infect
monkey
deliv
min
infect
pmoplu
compos
target
ebov
respect
iversen
et
al
protect
rhesu
monkey
lethal
infect
zair
ebola
viru
zebov
warren
et
al
similarli
pmoplu
compos
target
marburg
viru
respect
protect
cynomolgu
monkey
infect
lake
victoria
marburg
viru
marv
deliv
infect
iversen
et
al
therefor
pmoplu
hold
great
promis
treatment
patient
infect
highli
pathogen
virus
anoth
studi
research
group
show
pmoplu
target
alon
suffici
protect
monkey
lethal
ebov
infect
wherea
pmoplu
target
alon
fail
warren
et
al
result
thu
confirm
may
key
ebov
virul
factor
may
serv
promis
target
develop
effect
antiebov
treatment
strategi
picornavirus
nonenvelop
positivesens
singlestrand
rna
virus
belong
famili
picornavirida
famili
includ
genera
speci
zell
et
al
rna
genom
length
rang
kb
mani
picornavirus
import
human
anim
pathogen
includ
polioviru
coxsackieviru
enteroviru
footandmouth
diseas
viru
fmdv
vaccin
yet
exist
picornavirus
polioviru
fmdv
moreov
effect
antivir
therapi
yet
exist
treatment
infect
caus
pathogen
picornaviru
howev
ppmo
target
conserv
intern
ribosom
entri
site
ire
sequenc
shown
highli
effect
protect
cultur
cell
infect
human
rhinoviru
type
coxsackieviru
type
polioviru
type
stone
et
al
reduct
titer
ppmo
enterox
target
ire
sequenc
ident
human
enterovirus
rhinovirus
success
use
treat
polioviru
receptor
pvr
transgen
mice
prevent
infect
challeng
three
time
lethal
dose
ld
result
also
show
mice
receiv
ppmo
treatment
exhibit
approxim
higher
surviv
rate
control
signific
reduct
viral
titer
small
intestin
spinal
cord
brain
stone
et
al
coxsackieviru
primari
caus
viral
myocard
without
effect
therapi
studi
test
eight
ppmo
cultur
hela
cell
cardiomyocyt
well
murin
infect
model
yuan
et
al
among
eight
ppmo
test
design
target
portion
ire
especi
potent
replic
cultur
cell
cell
treat
prior
shortli
infect
viru
prolifer
significantli
inhibit
approxim
decreas
viral
titer
aj
mice
intraven
administr
prior
infect
significantli
reduc
cardiac
tissu
damag
notabl
decreas
myocardium
viru
titer
control
yuan
et
al
enteroviru
gener
caus
mild
handfootandmouth
diseas
sever
neurolog
complic
high
mortal
rate
report
one
studi
test
vivopmo
design
target
ire
rnadepend
rna
polymeras
rdrp
perform
tan
et
al
vivopmo
target
ire
significantli
reduc
replic
human
embryon
rhabdomyosarcoma
rd
cell
contrast
vivopmo
target
rdrp
less
effect
result
suggest
irestarget
vivopmo
potenti
antivir
candid
abrog
earli
infect
tan
et
al
fmdv
caus
highli
contagi
viral
diseas
clovenhoof
anim
lead
sever
econom
loss
livestock
industri
six
ppmo
design
target
utr
fmdv
genom
strain
cru
evalu
cultur
cell
vagnozzi
et
al
three
ppmo
target
domain
includ
portion
ire
two
translat
start
codoncontain
region
highli
effect
inhibit
fmdv
replic
low
micromolar
concentr
ppmo
led
dosedepend
sequencespecif
viru
titer
reduct
three
ppmo
target
genom
region
less
effect
vagnozzi
et
al
order
nidoviral
includ
famili
coronavirida
arterivirida
ronivirida
mesonivirida
cong
et
al
member
group
positivesens
singlestrand
rna
virus
coronavirida
arterivirida
includ
group
virus
infect
vertebr
mainli
mammalian
speci
wherea
two
famili
includ
virus
infect
invertebr
pmo
test
antivir
member
coronavirida
arterivirida
member
coronavirida
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
recent
identifi
potent
human
pathogen
cong
et
al
mous
hepat
viru
mhv
also
belong
famili
long
serv
model
understand
viral
hepat
human
assess
pmo
antivir
compound
neuman
et
al
burrer
et
al
ppmo
target
mhv
replicas
exhibit
low
toxic
dbt
astrocytoma
cell
cell
line
studi
mhv
infect
neuman
et
al
later
studi
test
ppmo
sever
mhv
strain
cell
cultur
vivo
use
mous
model
burrer
et
al
moulton
et
al
among
ten
ppmo
variou
viral
genom
target
site
ppmo
target
terminu
rna
genom
found
highli
effect
inhibit
six
differ
mhv
strain
mice
ppmo
treatment
led
prevent
virusinduc
tissu
damag
prophylact
treatment
ppmo
also
decreas
mhvinduc
weight
loss
prolong
postchalleng
surviv
studi
also
show
weight
loss
detect
histopatholog
chang
observ
prolong
ppmo
treatment
uninfect
mice
burrer
et
al
besid
ppmo
also
shown
inhibit
sarscov
replic
well
neuman
et
al
among
ppmo
test
two
ppmo
target
viral
transcriptionregulatori
sequenc
tr
within
utr
brought
signific
inhibit
cpe
reduc
celltocel
spread
administ
prior
peak
viral
prolifer
cultur
cell
neuman
et
al
member
arterivirida
includ
econom
import
viru
porcin
reproduct
respiratori
syndrom
viru
prrsv
prrsv
caus
contagi
swine
diseas
character
reproduct
failur
sow
respiratori
diseas
pig
age
diseas
plagu
global
swine
industri
sinc
first
report
current
strategi
use
prr
control
still
inadequ
du
et
al
research
laboratori
focus
develop
ppmo
prrsv
base
genom
sequenc
viral
protein
function
seri
ppmo
variou
target
design
includ
three
ppmo
target
end
utr
prrsv
genom
name
well
six
ppmo
target
translat
initi
region
orf
name
han
et
al
ppmo
target
utr
highli
effect
inhibit
prrsv
replic
cell
cultur
dosedepend
sequencespecif
manner
specif
ppmo
caus
reduct
prrsv
yield
moreov
also
demonstr
broad
inhibit
heterogen
prrsv
isol
addit
ppmo
target
utr
prrsv
genom
pair
ppmo
target
translat
initi
region
orf
respect
combin
enhanc
inhibit
heterolog
strain
north
american
prrsv
genotyp
effect
individu
vitro
han
et
al
inhibit
verifi
prrsv
rna
protein
express
level
sinc
ppmo
target
highli
conserv
sequenc
within
termin
region
prrsv
genom
effect
induc
inhibit
prrsv
replic
vitro
also
conduct
vivo
evalu
ppmo
opriessnig
et
al
prrsvneg
piglet
receiv
ppmo
intranas
h
infect
well
h
prrsv
infect
ppmo
treatment
well
toler
piglet
weight
chang
observ
across
piglet
group
ppmo
administr
significantli
reduc
prrsv
viremia
interstiti
pneumonia
moreov
alveolar
macrophag
isol
day
postinfect
elev
express
antivir
gene
ppmotreat
piglet
observ
well
opriessnig
et
al
besid
prrsv
antivir
effect
pmo
also
evalu
equin
arter
viru
eav
anoth
member
famili
arterivirida
van
den
born
et
al
similar
prrsv
studi
ppmo
design
target
termin
utr
eav
genom
remark
reduc
viru
replic
sequencespecif
doserespons
manner
howev
ppmo
target
termin
region
viral
genom
antigenom
result
moder
reduct
eav
replic
rel
high
concentr
ppmo
appli
moreov
ppmo
target
eav
tr
essenti
subgenom
rna
synthesi
ineffect
achiev
transcript
interfer
van
den
born
et
al
howev
ppmo
target
utr
eav
abl
cure
viral
infect
persist
infect
hela
cell
zhang
et
al
flaviviru
viral
genu
within
famili
flavivirida
genu
includ
west
nile
viru
wnv
dengu
viru
denv
yellow
fever
viru
zika
viru
sever
virus
may
caus
enceph
coffey
et
al
musso
gubler
except
yellow
fever
viru
effect
vaccin
antivir
drug
exist
flavivirus
prompt
evalu
pmo
sever
member
flaviviru
among
panel
ppmo
wnv
ppmo
target
termini
wnv
genom
design
end
csi
exhibit
greatest
potenc
block
wnv
replic
dea
et
al
moreov
treatment
wnvinfect
cell
either
end
csi
pmo
led
signific
reduct
viru
titer
approxim
without
appar
cytotox
ppmo
end
inhibit
wnv
translat
wherea
ppmo
csi
suppress
wnv
rna
replic
meanwhil
ppmo
csi
also
inhibit
mosquitoborn
flavivirus
target
csilik
sequenc
rel
conserv
respect
wnv
csi
target
sequenc
therefor
ppmo
target
conserv
cisact
element
flaviviru
genom
explor
antiflaviviru
therapeut
dea
et
al
recent
ppmo
end
csi
also
test
mous
model
wnv
infect
provid
partial
protect
administ
moreov
minim
ppmomedi
toxic
observ
toxic
observ
larger
dosag
dea
et
al
panel
ppmo
also
test
denv
kinney
et
al
wherebi
ppmo
target
termin
nucleotid
serotyp
denv
viru
genom
exhibit
rel
poor
suppress
viru
titer
howev
moder
reduct
titer
observ
ppmo
target
either
aug
translat
start
site
region
singl
open
read
frame
cycliz
sequenc
region
highli
effect
ppmo
sl
cs
target
termin
nucleotid
cycliz
sequenc
region
respect
reduc
viral
titer
greater
compar
control
day
postinfect
viru
notabl
treatment
cs
inhibit
replic
four
den
viru
serotyp
case
detect
limit
kinney
et
al
third
ppmo
design
target
top
stemloop
slt
inhibit
den
replic
bhk
cell
holden
et
al
inhibitori
mechan
studi
use
novel
report
replicon
report
mrna
result
demonstr
sl
inhibit
viral
translat
cs
block
viral
rna
synthesi
viral
translat
wherea
slt
inhibit
viral
translat
rna
synthesi
holden
et
al
recent
antidenv
ppmo
sl
cs
also
test
mice
andor
infect
intraperiton
ip
infect
mice
pfu
strain
new
guinea
c
shorten
surviv
day
sl
cs
administ
denv
infect
averag
surviv
time
extend
day
studi
also
includ
pharmacokinet
toxicolog
analysi
noninfect
anim
result
show
mice
high
concentr
ppmo
liver
follow
nine
consecut
oncedaili
ip
treatment
mgkg
ppmo
littl
impact
overal
mous
health
pmo
ppmo
also
studi
abil
prevent
treat
japanes
enceph
viru
jev
infect
well
ppmo
target
cycliz
sequenc
csi
jev
exhibit
signific
antivir
activ
vero
epitheli
neuron
macrophag
cell
nontox
concentr
anantpadma
et
al
addit
cell
infect
decreas
jev
replic
undetect
level
vero
cell
result
reduct
jev
titer
cell
respect
studi
antivir
effect
also
assess
vivo
treat
intracerebr
mgkg
dose
everi
h
day
mice
protect
lethal
dose
jev
anantpadma
et
al
meanwhil
test
vivopmo
target
utr
jev
genom
also
conduct
mice
nazmi
et
al
administr
intraperiton
inject
vivopmo
mgkg
bodi
weight
daili
day
immedi
jev
infect
mice
prolong
surviv
reduc
viral
load
viral
protein
express
brain
moreov
proinflammatori
cytokin
level
brain
normal
increas
jev
infect
reduc
follow
pmo
treatment
align
observ
reduc
microgli
activ
brain
well
nazmi
et
al
chikungunya
viru
chikv
caus
infect
human
associ
debilit
persist
arthralgia
arthriti
two
ppmo
design
target
highli
conserv
sequenc
present
chikv
nonstructur
structur
polyprotein
lam
et
al
ppmo
target
aug
region
significantli
suppress
chikv
replic
hela
cell
administ
infect
notabl
neonat
mice
administr
infect
confer
surviv
chikv
diseas
lam
et
al
ppmo
also
test
antivir
effect
toward
group
v
ssrna
viru
famili
includ
pneumovirida
paramyxovirida
orthomyxovirida
arenavirida
other
respiratori
syncyti
viru
rsv
member
famili
pneumovirida
major
caus
lower
respiratori
tract
infect
infant
young
children
highrisk
adult
current
vaccin
exist
prevent
rsv
infect
howev
two
antisens
ppmo
design
target
termin
region
translat
start
site
rsv
l
mrna
test
exhibit
minim
cytotox
lai
et
al
ppmo
inhibit
rsv
replic
reduc
viral
titer
administ
rsv
intranas
inocul
ppmo
protect
balbc
mice
infect
reduc
viral
titer
lung
tissu
attenu
pulmonari
inflamm
lai
et
al
measl
viru
mev
member
famili
paramyxovirida
mev
highli
contagi
human
pathogen
treat
effect
avail
antivir
compound
prevent
use
vaccin
five
ppmo
target
mev
genom
rna
mrna
test
cultur
cell
sleeman
et
al
ppmo
target
conserv
sequenc
translat
start
site
mrna
code
viral
nucleocapsid
protein
highli
effect
multipl
genotyp
mev
sleeman
et
al
influenza
viru
member
famili
orthomyxovirida
relentless
ongo
global
public
health
concern
deliv
intranas
administr
ppmo
inhibit
replic
equin
influenza
viru
fluav
mice
exhibit
toxic
effect
antivir
concentr
vivo
lupfer
et
al
meanwhil
ppmo
panel
develop
target
rna
genom
segment
encod
polymeras
subunit
highli
pathogen
mouseadapt
influenza
viru
strain
gabriel
et
al
studi
viru
replic
mdck
cell
significantli
inhibit
three
ppmo
target
either
translat
start
site
region
np
mrna
termin
region
np
viral
rna
vrna
mous
model
ppmo
target
region
np
vrna
administ
intranas
h
day
intranas
infect
lethal
dose
treat
mice
exhibit
significantli
lower
viral
titer
lung
greater
surviv
versu
untreat
control
durat
experi
gabriel
et
al
besid
target
virus
ppmo
also
test
efficaci
host
mrna
encod
proteas
crucial
viral
infect
ppmo
block
host
proteas
cleavag
influenza
viru
hemagglutinin
ha
inhibit
viral
infect
treatment
human
airway
epitheli
cell
ppmo
design
interfer
splice
hacleav
proteas
premrna
result
product
mrna
lack
exon
result
product
enzymat
inact
form
bottcherfriebertshaus
et
al
ultim
ppmo
shown
prevent
cleavag
variou
human
season
pandem
influenza
virus
lead
signific
reduct
viral
titer
bottcherfriebertshaus
et
al
viru
threat
human
health
member
arenavirida
famili
caus
mening
hemorrhag
fever
ppmo
design
interfer
translat
shown
effect
reduc
viru
replic
neuman
et
al
cultur
cell
ppmo
target
sequenc
locat
termini
genom
segment
highli
conserv
across
arenavirus
consequ
ppmo
effect
viru
tacarib
viru
pichind
viru
also
lymphocyt
choriomening
viru
lcmv
wherebi
suppress
viral
titer
liver
lcmvinfect
mice
neuman
et
al
genu
alphaviru
includ
positivesens
rna
virus
threaten
human
health
paessler
et
al
sindbi
viru
sinv
member
famili
togavirida
ppmo
target
terminu
aug
translat
start
site
sinv
genom
significantli
suppress
sinv
replic
tissu
cultur
paessler
et
al
venezuelan
equin
enceph
viru
veev
anoth
member
togavirida
ppmo
target
veev
region
correspond
sinv
region
mention
inhibit
sever
strain
veev
vitro
notabl
mice
pretreat
pmo
protect
lethal
veev
infect
partial
protect
observ
mice
receiv
postinfect
pmo
treatment
paessler
et
al
norovirus
belong
calicivirida
famili
nonenvelop
positivesens
singlestrand
rna
virus
genom
approxim
kb
length
encod
three
orf
norovirus
caus
nonbacteri
epidem
gastroenter
bok
et
al
ppmo
target
first
aug
region
near
end
murin
noroviru
mnv
genom
effect
inhibit
mnv
replic
cultur
cell
bok
et
al
moreov
consensu
ppmo
target
correspond
end
genom
sever
divers
human
noroviru
genotyp
also
inhibit
norwalk
viru
protein
express
speci
noroviru
repliconbear
cell
cellfre
luciferas
report
assay
bok
et
al
similar
norovirus
hepat
e
viru
hev
positivesens
singlestrand
rna
viru
contain
three
orf
current
classifi
within
famili
hepevirida
nan
zhang
hev
share
similar
genom
structur
member
calicivirida
previous
classifi
famili
nan
zhang
studi
demonstr
ppmo
target
termin
hev
genom
start
codon
highli
effect
hev
genotyp
infect
vitro
nan
et
al
moreov
ppmo
target
utr
hev
genom
terminu
antisens
hev
rna
also
block
hev
replic
lesser
extent
achiev
ppmo
target
terminu
nan
et
al
sinc
utr
terminu
antisens
hev
rna
gener
consid
bind
site
hev
rnadepend
rna
polymeras
rdrp
appear
ppmomedi
steric
blockad
also
appli
rdrp
well
nan
et
al
compar
pmo
applic
rna
virus
pmo
use
dna
virus
much
less
studi
date
member
herpesvirida
test
pmomedi
inhibit
research
lab
evalu
pmo
kaposi
sarcomaassoci
herpesviru
kshv
kshv
also
known
human
herpesviru
human
oncoviru
belong
gamma
herpesviru
subfamili
kshv
associ
kaposi
sarcoma
ks
two
bcell
lymphoprolif
diseas
primari
effus
lymphoma
pel
multicentr
castleman
diseas
mcd
purushothaman
et
al
diseas
aidsrel
malign
hivinfect
patient
kshv
infect
human
exhibit
either
lifelong
immunolog
silent
latent
infect
transient
lytic
infect
distinct
viral
geneexpress
profil
lagunoff
et
al
bechtel
et
al
predominantli
latent
state
kshv
infect
kshv
genom
maintain
circular
extrachromosom
dna
replic
insid
host
cell
cell
cycledepend
manner
express
key
viral
regul
latencyassoci
nuclear
antigen
lana
encod
viral
cyclin
vcyclin
encod
viral
flip
vflip
encod
observ
latenc
uppal
et
al
upon
reactiv
assum
lytic
infect
state
full
repertoir
lytic
viral
gene
includ
transcript
activ
rta
viral
viral
g
proteincoupl
receptor
vgpcr
viral
chemokin
express
temporallyregul
manner
purushothaman
et
al
base
function
kshv
latent
lytic
gene
panel
ppmo
design
set
gene
includ
lana
rta
zhang
et
al
zhang
et
al
zhang
et
al
treatment
kshvposit
pel
cell
rtaspecif
ppmo
reduc
rta
express
also
caus
downregul
sever
earli
late
kshv
gene
product
includ
moreov
kshv
dna
copi
number
ppmo
pel
cell
cultur
supernat
reduc
demonstr
inhibit
kshv
lytic
replic
zhang
et
al
furthermor
treatment
cell
ppmo
lana
reduc
lana
express
zhang
et
al
meanwhil
ppmo
also
evalu
viral
homologu
proinflammatori
cytokin
believ
contribut
vascular
permeabl
format
pel
effus
sakakibara
tosato
cytokin
share
low
signific
homolog
human
irf
famili
member
act
oncogen
inhibit
interferon
induct
gao
et
al
treatment
pel
cell
ppmo
design
mrna
led
mark
reduct
proport
pel
cell
reduc
growth
pel
cell
kshv
dna
level
zhang
et
al
meanwhil
ppmo
target
also
shown
inhibit
viral
dna
replic
addit
block
express
cell
zhang
et
al
interestingli
reduct
express
kshvinfect
cell
result
higher
express
level
cellular
signal
transduc
activ
transcript
zhang
et
al
encourag
vitro
data
vivo
evalu
ppmo
effect
express
multipl
viral
gene
conduct
zhang
et
al
howev
vivo
result
defi
expect
drawn
vitro
studi
specif
ppmo
demonstr
promis
vivo
inhibit
wherebi
scid
mice
treat
ppmo
exhibit
engraft
kshvinfect
pel
cell
remain
healthi
throughout
studi
zhang
et
al
convers
scid
mice
receiv
combin
pmo
two
trend
less
engraft
kshvinfect
pel
cell
differ
result
statist
signific
treat
control
mice
therefor
ppmo
target
select
use
vitro
assess
may
achiev
expect
inhibit
vivo
emphas
fact
care
valid
use
adequ
anim
model
necessari
acyclovir
acv
nucleic
acid
analog
guanosin
use
treat
hsv
viral
resist
acv
becom
recent
concern
potenti
treatment
acvresist
hsv
ppmo
resist
evalu
vitro
mous
model
well
select
viru
ppmo
target
act
ubiquitin
ligas
antagon
host
innat
immun
halford
et
al
lanfranca
et
al
multipl
function
regul
involv
premrna
splice
host
innat
immun
respons
christensen
et
al
tang
et
al
ppmo
target
translat
start
site
region
mrna
appli
soon
infect
cultur
cell
reduct
yield
observ
assess
reduc
plaqu
format
moreov
ppmo
also
inhibit
acvresist
plaqu
format
equival
dose
acv
led
plaqu
reduct
moerdykschauweck
et
al
vivo
data
suggest
ppmo
welltoler
uninfect
mice
day
administr
moerdykschauweck
et
al
topic
applic
ppmo
eye
mice
reduc
incid
eye
diseas
compar
control
therefor
ppmo
hold
promis
antivir
drug
use
treat
ocular
infect
moerdykschauweck
et
al
regard
ppmo
target
mrna
also
highli
effect
either
nonacvresist
acvresist
strain
one
vivo
studi
ppmo
welltoler
balbc
mice
cotton
rat
cotton
rat
receiv
ppmo
h
inocul
show
reduct
genit
lesion
reduct
mortal
day
postinfect
mice
receiv
combin
regimen
ppmo
inocul
complet
free
genit
viral
infect
day
postinocul
eid
et
al
varieti
studi
suggest
pmo
would
good
candid
antivir
therapeut
emerg
reemerg
virus
absenc
effect
therapi
howev
effect
target
sequenc
pmo
design
need
care
valid
list
previous
publish
effect
viru
target
region
use
pmo
design
rna
virus
briefli
summar
tabl
date
pmo
evalu
positivesens
rna
virus
target
sequenc
pmo
mainli
locat
termin
end
viral
genom
tabl
notabl
appear
mrnalik
properti
positivesens
rna
viru
genom
make
highli
suscept
pmomedi
translat
inhibit
pmo
pair
sequenc
locat
termin
end
viral
genom
except
moreov
utr
either
end
viral
genom
gener
conserv
among
viral
strain
convers
positivesens
rna
virus
pmo
target
termin
end
viral
genom
test
well
howev
data
appear
mix
terminaltarget
pmo
one
hand
member
flavivirida
pmo
target
cycliz
sequenc
locat
within
termin
end
highli
effect
inhibit
viru
replic
dea
et
al
dea
et
al
kinney
et
al
holden
et
al
stein
et
al
anantpadma
et
al
nazmi
et
al
hand
use
pmo
target
either
termin
region
viral
genom
neg
genom
strand
result
moder
reduct
eav
van
den
born
et
al
result
suggest
pmo
target
termin
end
less
effect
inhibit
eav
replic
compar
pmo
target
termin
utr
eav
genom
therefor
viral
genom
end
prefer
target
region
antivir
pmo
design
positivesens
rna
virus
addit
pmo
target
within
termin
end
positivesens
rna
viru
genom
pmo
target
rna
secondari
structur
also
consid
especi
common
conserv
element
among
rna
virus
ire
sequenc
gener
unstructur
region
access
oligonucleotid
bind
structur
region
sinc
intern
structur
within
target
rna
imped
pmo
bind
childsdisney
disney
howev
case
direct
target
ire
sequenc
could
inhibit
replic
virus
includ
member
order
picornaviral
yuan
et
al
stone
et
al
tan
et
al
therefor
deep
analysi
secondari
structur
target
rna
may
aid
pmo
target
select
pmo
evalu
antivir
activ
negativesens
rna
virus
current
report
mainli
focu
block
translat
individu
viral
gene
rather
direct
target
rna
genom
exampl
pmo
target
ebov
alon
suffici
protect
monkey
lethal
ebov
infect
wherea
pmoplu
formul
design
target
fail
warren
et
al
therefor
screen
find
effect
pmo
target
negativesens
rna
virus
may
requir
care
consider
need
positivesens
rna
virus
although
yet
extens
studi
pmo
target
select
appear
complic
larg
dna
virus
herpesvirus
due
larg
genom
size
dna
virus
encod
mani
gene
includ
indispens
dispens
gene
one
hand
indispens
gene
studi
far
appear
good
pmo
target
exampl
earli
gene
encod
viral
dna
polymeras
larg
subunit
ribonucleotid
reductas
respect
essenti
viral
dna
replic
eid
et
al
howev
block
mrna
translat
pmo
significantli
reduc
viral
replic
transmiss
infect
cell
eid
et
al
hand
dna
virus
encod
mani
dispens
accessori
protein
multipl
function
antagonist
host
innat
immun
gene
need
care
valid
vitro
vivo
use
pmo
target
exampl
pmo
target
kshv
demonstr
littl
protect
kshvinfect
pel
engraft
scid
mice
spite
effect
pmo
target
vitro
zhang
et
al
asid
challeng
regard
target
select
emerg
resist
viru
sequencespecif
therapi
anoth
common
challeng
face
antivir
inde
hcmv
mutant
sequencedepend
resist
phosphorothio
oligonucleotid
fomivirsen
discov
almost
simultan
market
approv
drug
mulamba
et
al
pmobas
antivir
therapi
sequencespecif
pmoresist
target
mutat
would
abolish
pmo
inhibit
alreadi
observ
neuman
et
al
west
nile
viru
sequenc
ppmoresist
wnv
mutant
demonstr
virus
resist
end
ppmo
treatment
contain
two
three
mismatch
within
ppmobind
site
wherea
csi
ppmoresist
virus
accumul
mutat
outsid
ppmotarget
region
dea
et
al
meanwhil
ppmoresistantwnv
infect
mice
shown
antagon
pmomedi
protect
viru
dea
et
al
similar
pmoresist
report
ebola
viru
treatment
pmo
target
ebola
viru
well
kugelman
et
al
therefor
mutat
within
outsid
pmotarget
sequenc
might
lead
pmo
resist
futur
challeng
research
ppmo
inhibit
prrsv
multipl
reduct
viral
rna
copi
achiev
pmo
sequenc
complementari
conserv
region
within
utr
prrsv
genom
although
low
level
viral
rna
replic
still
observ
suggest
pmoresist
mutant
might
arisen
effect
one
possibl
strategi
encount
pmoresist
mutant
would
incorpor
promiscu
base
inosin
compens
predict
basepair
mismatch
howev
challeng
accur
predict
potenti
mutat
nucleotid
within
pmotarget
sequenc
therefor
pmo
target
sequenc
specif
rna
viru
must
care
select
minim
gener
mutant
moreov
use
multipl
pmo
differ
target
viru
may
help
avoid
mutant
viru
gener
altern
strategi
prevent
pmoresist
viru
indirect
inhibit
host
factor
essenti
viru
replic
current
one
studi
conduct
influenza
viru
exploit
fact
cleavag
viral
hemagglutinin
host
proteas
crucial
viral
infect
studi
treatment
human
airway
epitheli
cell
ppmo
design
interfer
premrna
splice
host
proteas
respons
cleavag
result
mrna
lack
exon
final
led
express
enzymat
inact
form
bottcherfriebertshaus
et
al
therefor
block
cleavag
ppmo
confirm
differ
human
season
pandem
influenza
virus
result
signific
reduct
viral
titer
bottcherfriebertshaus
et
al
addit
investig
varieti
host
protein
identifi
essenti
factor
requir
viru
replic
host
defens
viral
pathogenesi
recent
year
rajsbaum
et
al
tripathi
et
al
put
ubiquitin
ligas
identifi
novel
host
factor
involv
bud
influenza
virion
tripathi
et
al
target
factor
could
block
releas
influenza
viru
although
unknown
could
employ
envelop
virus
bud
well
possibl
target
commonli
use
host
factor
requir
viral
replic
could
broaden
antivir
spectrum
pmo
therefor
applic
pmo
target
host
factor
antivir
strategi
may
avoid
gener
pmoresist
viru
also
expand
antivir
spectrum
long
target
host
factor
employ
differ
viru
replic
two
decad
sinc
first
approv
antisensebas
therapi
pmo
becom
import
analog
driven
develop
antisens
therapi
efficaci
safeti
demonstr
recent
fda
approv
eteplirsen
inde
biolog
stabil
neutral
charg
rnase
hindepend
mechan
action
uniqu
pmo
featur
moreov
besid
develop
antivir
compound
pmo
evalu
anticanc
antibacteri
agent
ongo
enterlein
et
al
warfield
et
al
cansizoglu
toprak
chen
et
al
summerton
sinc
pmo
good
track
record
use
tool
development
biolog
therapeut
agent
three
gener
pmo
develop
unmodifi
pmo
conjug
pmo
pmoplu
improv
intracellular
deliveri
dali
et
al
howev
sever
issu
remain
unresolv
pmo
adopt
widespread
use
one
hand
studi
need
establish
conveni
rout
pmo
administr
vivo
vivo
studi
pmo
administr
via
either
intraven
intramuscular
inject
although
report
demonstr
pmo
administ
via
intranas
deliveri
inhibit
replic
virus
respiratori
tract
tropism
opriessnig
et
al
rajsbaum
notabl
vivo
studi
employ
pmo
antivir
agent
two
respiratori
virus
influenza
viru
prrsv
opriessnig
et
al
rajsbaum
sinc
investig
conduct
see
intraven
intramuscular
administr
pmo
also
effect
influenza
viru
prrsv
possibl
intranas
deliveri
pmo
prefer
viru
caus
respiratori
infect
moreov
also
possibl
virusspecif
deliveri
rout
base
initi
infect
site
may
offer
better
antivir
effici
rather
use
intraven
rout
univers
way
pmo
administr
hand
although
pmo
highli
adapt
platform
deliveri
nucleic
acid
sequencespecif
drug
select
effect
target
avoid
emerg
mutant
viru
also
requir
investig
issu
could
properli
address
pmo
serv
promis
strategi
treatment
varieti
diseas
includ
difficulttotreat
viral
infect
gener
true
antivir
drug
develop
high
efficaci
low
toxic
good
pharmacokinet
good
bioavail
low
cost
characterist
sought
pmo
compound
result
discuss
review
show
great
promis
warrant
research
develop
safe
effect
antisens
treatment
varieti
human
diseas
yn
yjz
design
manuscript
yn
prepar
main
bodi
manuscript
yjz
prepar
figur
revis
manuscript
author
approv
public
